WO2014193237A3 - C diff protease - Google Patents

C diff protease Download PDF

Info

Publication number
WO2014193237A3
WO2014193237A3 PCT/NL2014/050349 NL2014050349W WO2014193237A3 WO 2014193237 A3 WO2014193237 A3 WO 2014193237A3 NL 2014050349 W NL2014050349 W NL 2014050349W WO 2014193237 A3 WO2014193237 A3 WO 2014193237A3
Authority
WO
WIPO (PCT)
Prior art keywords
protease
diff
peptide
invention further
clostridium difficile
Prior art date
Application number
PCT/NL2014/050349
Other languages
French (fr)
Other versions
WO2014193237A2 (en
Inventor
Hans Christiaan VAN LEEUWEN
Paul Jacob HENSBERGEN
Jan Wouter Drijfhout
Eduard KUIJPER
Jeroen CORVER
Original Assignee
Academisch Ziekenhuis Leiden H.O.D.N. Lumc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden H.O.D.N. Lumc filed Critical Academisch Ziekenhuis Leiden H.O.D.N. Lumc
Publication of WO2014193237A2 publication Critical patent/WO2014193237A2/en
Publication of WO2014193237A3 publication Critical patent/WO2014193237A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Abstract

The invention relates to a peptide comprising the amino acid sequence A/P- A/P-V/P/I/C/T-P as a substrate for the protease CD2830 of Clostridium difficile. The invention further relates to kit or device comprising the peptide for determining the presence of Clostridium difficile in a sample and for identifying an agent that is capable of modulating protease activity of CD2830. The invention further relates to a composition, preferably a pharmaceutical composition, comprising an inhibitor of the protease activity of CD2830.
PCT/NL2014/050349 2013-05-30 2014-05-30 C diff protease WO2014193237A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13169930 2013-05-30
EP13169930.8 2013-05-30
EP13197876.9 2013-12-17
EP13197876 2013-12-17

Publications (2)

Publication Number Publication Date
WO2014193237A2 WO2014193237A2 (en) 2014-12-04
WO2014193237A3 true WO2014193237A3 (en) 2015-03-19

Family

ID=50928203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2014/050349 WO2014193237A2 (en) 2013-05-30 2014-05-30 C diff protease

Country Status (1)

Country Link
WO (1) WO2014193237A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060121544A1 (en) * 1997-09-15 2006-06-08 Annegret Boge Molecular modification assays
WO2009010765A2 (en) * 2007-07-18 2009-01-22 Novacta Biosystems Limited Lantibiotic-based compounds having antimicrobial activity
US20100291100A1 (en) * 2009-03-27 2010-11-18 Gojo Industries, Inc. Compositions And Methods For Screening And Using Compounds Antagonizing Spore-Surface Interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737977T2 (en) 1997-05-01 2008-04-17 Minnesota Mining And Manufacturing Company, St. Paul FLUOROGENE PROTEASE SUBSTRATES BASED ON COLOR DIMERIZATION
EP1354201A2 (en) 2000-02-11 2003-10-22 Cellomics, Inc. Peptide biosensors for anthrax protease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060121544A1 (en) * 1997-09-15 2006-06-08 Annegret Boge Molecular modification assays
WO2009010765A2 (en) * 2007-07-18 2009-01-22 Novacta Biosystems Limited Lantibiotic-based compounds having antimicrobial activity
US20100291100A1 (en) * 2009-03-27 2010-11-18 Gojo Industries, Inc. Compositions And Methods For Screening And Using Compounds Antagonizing Spore-Surface Interactions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JACQUOT ET AL: "High affinity Grb2-SH3 domain ligand incorporating C<b>eta-substituted prolines in a Sos-derived decapeptide", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 15, no. 3, 19 January 2007 (2007-01-19), pages 1439 - 1447, XP005823084, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2006.11.002 *
M. VIDAL ET AL: "Design of Peptoid Analogue Dimers and Measure of Their Affinity for Grb2 SH3 Domains +", BIOCHEMISTRY, vol. 43, no. 23, 1 June 2004 (2004-06-01), pages 7336 - 7344, XP055087222, ISSN: 0006-2960, DOI: 10.1021/bi030252n *

Also Published As

Publication number Publication date
WO2014193237A2 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
CA3081446A1 (en) Methods and compositions for polypeptide analysis
MX2021012926A (en) Imide-based modulators of proteolysis and associated methods of use.
MX2021010482A (en) Compounds and methods for the enhanced degradation of targeted proteins.
MX2017015605A (en) Imide-based modulators of proteolysis and associated methods of use.
MX2022009478A (en) Compounds &amp; methods for the enhanced degradation of targeted proteins &amp; other polypeptides by an e3 ubiquitin ligase.
MX2020003260A (en) Fc-receptor binding modified asymmetric antibodies and methods of use.
SG10201806926YA (en) Method for masking bitterness of composition containing collagen peptide
CL2013003145A1 (en) Pharmaceutical formulation comprising mixture of anti-alpha4 beta7 antibody, an antioxidant or chelator and at least one free amino acid.
MX2016015511A (en) Compound containing self-immolative group.
MX2015006324A (en) Methods for the manufacture of proteolytically processed polypeptides.
WO2013020108A3 (en) Bile acid recycling inhibitors for treatment of pancreatitis
MX2017005575A (en) Pharmaceutical anti-tnf-alpha antibody formulation.
MX2020003096A (en) Pharmaceutical formulations of a hif hydroxylase inhibitor.
CR20170197A (en) PROTEINS OF VARIANTS OF SEQUENCES OF AMINO ACIDS OF CRY1DA1 ACTIVE FOR LEPIDOPTERS
PH12016500101A1 (en) Protease-resistant peptide ligands
GB201014028D0 (en) In-situ reagent
NZ727701A (en) Platinum compounds, compositions, and uses thereof
PE20160218A1 (en) METHODS TO CONTROL LEVELS OF FUCOSILATION IN PROTEINS
WO2014172638A3 (en) Inhibitors of deubiquitinating proteases
EA201792608A2 (en) APPLICATION OF P3 BACTERIOPHAG PROTEIN AS AN AGYLINES CONNECTING AMYLOID
WO2017021004A8 (en) Chromogenic and fluorogenic peptide substrates for the detection of serine protease activity
EP3696190A3 (en) Methods
EP3337791A4 (en) Inhibitors of peptidyl arginine deiminase (pad) enzymes and uses thereof
WO2012166848A3 (en) Methods and compositions for the detection of functional clostridium difficile toxins
EP3004375A4 (en) Protease-responsive peptide biosensors and methods for analyte detection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14729469

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14729469

Country of ref document: EP

Kind code of ref document: A2